IL-4: PREDIKTOR ANTI INFLAMASI PADA STROKE ISKEMIK ?
DOI:
https://doi.org/10.19166/med.v5i1.1178Abstract
The brain ischemia due to vascular occlusion, especially in the main cerebral artery, could trigger the microglia as a natural immune cell in the brain. These activated microglia will turn up the inflammation cascade in the ischemic area. Interleukin-4 (IL-4) has a vital role in the microglial alteration to become an anti-inflammatory phenotype, which wind up the expression of MHC II and CD11c. Moreover, previous studies has supported that the stimulation of IL-4 in the culture of microglia/macrophage will produce this kind of “alternative” phenotype or neuroprotective phenotype, through the fall of TNF and rise of IGF-1. However, only a few have discussed the role and profile of IL-4 in ischemic stroke. This review article will cover the possibility of IL-4 role as an anti-inflammatory predictor in ischemic stroke.
Keywords: Interleukin-4, microglia, ischemic stroke, inflammation
References
Abbas A.K., Lichtman A.H., Pillai S., 2012. Cellular and Molecular Immunology. 7th ed. Elsevier Saunders.
Brait V.H., Arumugam T.V., Drummond G.R., Sobey C.G., 2012. Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia. J Cereb Blood Flow Metab. 32: 598 - 611.
Brodie, C., N. Goldreich, T. Haiman, and G. Kazimirsky. 1998. Functional IL-4 receptors on mouse astrocytes: IL-4 inhibits astrocyte activation and induces NGF secretion. J. Neuroimmunol. 81: 20-30.
Butovsky, O., Bukshpan S., Kunis G., Jung S., and Schwartz M., 2007. Microglia can be induced by IFN-gamma or IL-4 to express neural or dendritic-like markers. Mol. Cell. Neurosci. 35: 490-500.
Caplan, L.R., 2009. Caplan’s Stroke: A Clinical Approach. 4rd ed. Saunders, Philadelphia.
Chao, C. C., Hu S., and Peterson P.K., 1995. Modulation of human microglial cell superoxide production by cytokines. J. Leukoc. Biol. 58: 65-70.
Chhor V., Charpentier T.L., Lebon S., et al, 2013. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun. 32: 70 - 85.
Colton C.A., 2009. Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol. 4: 399-418.
Di Carlo A., 2009. Human and Economic Burden of Stroke. Age Ageing. 38:4-5.
Garden, G.A and Moller, T., 2006. Microglia Biology in Health and Disease. J Neuroimmune Pharmacol. 1:127-137.
Hu X., Li P., Guo Y., Wang H., et al, 2012. Microglia/Macrophage Polarization Dynamics Reveal Novel Mechanism of Injury Expansion After Focal Cerebral Ischemia. Stroke. 43:3063-3070.
Hart, P. H., Vitti G.F., Burgess D.R., Whitty G.A., Piccoli D.S., and Hamilton J.A., 1989. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. Proc. Natl. Acad. Sci. USA 86: 3803-3807.
Howard, M., et al, 1982. Identification of a T cell-derived b cell growth factor distinct from interleukin 2. J. Exp. Med. 155: 914-923.
Iadecola C and Anrather J., 2011. The Immunology of Stroke: from Mechanism to Translation. Nat Med. 17: 796-808.
Jauch, E.C.J. 2005. Biomarker Advances in Acute Ischemic Stroke. In: Advancing the Standard of Care: Cardiovascular and Neurovascular Emergencies. Division of Emergency Medicine, Washington University School of Medicine, Cincinnati.
Jin R., Yang G., and Li G., 2010. Inflammatory Mechanisms in Ischemic Stroke: Role of Inflammatory Cells. 2010. J. Leukoc. Biol. 87: 000-000.
Kim H.M., Shin H.Y., Jeong H.J., An H.J., et al, 2000. Reduced IL-2 but elevated IL-4, IL-6, and IgE serum levels in patients with cerebral infarction during the acute stage. J. Mol. Neurosci. 14: 191-196.
Liesz A, Hagmann S, Zschoche C, et al, 2009. The spectrum of systemic immune alterations after murine focal ischemia: Immunodepression versus immunomodulation. Stroke. 40:2849-2858.
Lyons, A., Downer E.J., Crotty S., Nolan Y.M., Mills K.H., and Lynch M.A., 2007. CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. J Neurosci. 27: 8309-8313.
Major J., Fletcher J.E., and Hamilton T.A., 2002. IL-4 pretreatment selectively enhances cytokine and chemokine production in lipopolysaccharide-stimulated mouse peritoneal macrophages. J. Immunol. 168: 2456-2463.
Milner J. D., et al, 2010. Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulation. Blood 116: 2476-2483.
Ramalingam T. R., Pesce J.T., Sheikh F., et al, 2008. Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat Immunol. 9: 25-33.
Riset Kesehatan Dasar, 2013. Badan Penelitian dan Pengembangan Kesehatan Kementrian Kesehatan RI.
Saenger A.K. and Christenson R.H., 2010. Stroke Biomarkers: Progress and Challenges for Diagnosis, Prognosis, Differentiation, and Treatment. Clin Chem. 56:21-33.
Shichita T, Sakaguchi R, Suzuki M, Yoshimura A., 2012. Post-ischemic inflammation in the brain. Frontiers in Immunology. Volume 3. Article 132.
Theodorou G.L., Marousi S., Ellul J., et al, 2008. T helper 1 (Th1) / Th2 cytokine expression shift of peripheral blood CD4+ and CD8+ T cells in patients at the post-acute phase of stroke. Clin Exp Immunol. 152: 456 - 463.
Xiong X., Barreto G., Xu L., Ouyang Y., Xie X., Giffard R.G., 2011. Increased brain injury and worsened neurological outcome in IL-4 Knockout Mice Following Transient Focal Cerebral Ischemia. Stroke. 42: 2026 - 2032.
Yayasan Stroke Indonesia. 24 Juni Hari Stroke Sedunia 2008, (http://www.yastroki.or.id/read.php?id=232, diakses 23 Mei 2008).
Zee R.Y.L., Cook N.R., Cheng S., et al, 2004. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum Mol Genet. 13: 389 - 396.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website). The final published PDF should be used and bibliographic details that credit the publication in this journal should be included.
.png)
